The advancement of molybdenum disulfide quantum dots nanoparticles as nanocarrier for drug delivery systems: Cutting-edge in dual therapeutic roles

The advancement of nanomedicines utilizing MoS 2 has unveiled fresh avenues in treating cancer. MoS 2 , particularly in MoS 2 quantum dots (MoS 2 QDs) with diverse structures, has displayed encouraging outcomes in precise and controlled drug delivery to specific sites, resulting in decreased side effects and heightened therapeutic efficacy. MoS 2 QDs are generating interest for their unique properties, thanks to edge states in these van der Waals quantum dots, enabling versatile chemical modifications. Evaluating MoS 2-based drug delivery systems for potential clinical application underscores the necessity of straightforward, scalable, and biocompatible compositions. Enhancing the enhanced permeability and retention (EPR) effects, optimizing drug bioavailability, and ensuring dosage-dependent efficacy are crucial for favorable treatment outcomes. Additionally, addressing concerns regarding drug distribution and elimination to minimize potential adverse reactions is essential. Moreover, safeguarding against premature degradation during transit is crucial for achieving optimal therapeutic results. This article thoroughly discusses properties, synthesis methods, and the release of pharmaceutical nanosystems, along with drug release mechanisms, chemodynamic therapy, photodynamic therapy, photothermal therapy, and biosensing.